Table 1.
Demographics of propensity score-matched patients with breast cancer receiving total mastectomy under PB-RA with propofol or INHA-GA without propofol.
| INHA-GA without propofol N = 707 | PB-RA with propofol N = 707 | p-value | ||||
|---|---|---|---|---|---|---|
| n | (%) | n | (%) | |||
| Age (years) | Mean (SD) | 56.4 | (12.4) | 56.1 | (12.4) | 0.9999 |
| Median (Q1–Q3) | 56 | (47-64) | 55 | (47-64) | ||
| 20–49 | 236 | (33.4) | 236 | (33.4) | 1.0000 | |
| 50+ | 471 | (66.6) | 471 | (66.6) | ||
| Diagnosis year | 2009–2013 | 210 | (29.7) | 210 | (29.7) | 1.0000 |
| 2014–2018 | 497 | (70.3) | 497 | (70.3) | ||
| Menopausal status | Premenopausal | 282 | (39.9) | 282 | (39.9) | 1.0000 |
| Postmenopausal | 425 | (60.1) | 425 | (60.1) | ||
| CCI scores | 0 | 478 | (67.6) | 476 | (67.3) | 0.6530 |
| 1 | 148 | (20.9) | 149 | (21.1) | ||
| 2+ | 81 | (11.5) | 82 | (11.6) | ||
| Differentiation | I | 68 | (9.6) | 68 | (9.6) | 1.0000 |
| II | 486 | (68.7) | 486 | (68.7) | ||
| III | 153 | (21.6) | 153 | (21.6) | ||
| AJCC clinical stage | I | 206 | (29.1) | 206 | (29.1) | 1.0000 |
| II | 382 | (54.0) | 382 | (54.0) | ||
| III | 119 | (16.8) | 119 | (16.8) | ||
| pT | pT1 | 269 | (38.0) | 269 | (38.0) | 1.0000 |
| pT2 | 345 | (48.8) | 345 | (48.8) | ||
| pT3–4 | 93 | (13.2) | 93 | (13.2) | ||
| pN | pN0 | 369 | (52.2) | 369 | (52.2) | 1.0000 |
| pN1 | 184 | (26.0) | 184 | (26.0) | ||
| pN2–3 | 154 | (21.8) | 154 | (21.8) | ||
| ASA physical status | ASA I | 400 | (56.6) | 384 | (54.3) | 0.5510 |
| ASA II | 167 | (23.6) | 172 | (24.3) | ||
| ASA III–IV | 140 | (19.8) | 151 | (21.4) | ||
| Adjuvant chemotherapy | No | 254 | (35.9) | 243 | (34.4) | 0.7214 |
| Yes | 453 | (64.1) | 464 | (65.6) | ||
| Adjuvant RT | No | 410 | (58.0) | 419 | (59.3) | 0.3952 |
| Yes | 297 | (42.0) | 288 | (40.7) | ||
| HR status | No | 373 | (52.8) | 375 | (53.0) | 0.7520 |
| Yes | 334 | (47.2) | 332 | (47.0) | ||
| HER2 status | No | 577 | (81.6) | 586 | (82.9) | 0.5149 |
| Yes | 130 | (18.4) | 121 | (17.1) | ||
| Nodal surgery | ALND | 510 | (72.1) | 508 | (71.9) | 0.8629 |
| SLNB | 197 | (27.9) | 199 | (28.1) | ||
| Hospital level | Academic centers | 553 | (78.2) | 553 | (78.2) | 1.0000 |
| Nonacademic | 154 | (21.8) | 154 | (21.8) | ||
| Follow-up time, months | Mean (SD) | 55.9 | (26.6) | 43.3 | (29.8) | 0.7298 |
| All-cause death | 79 | (11.2) | 66 | (9.3) | 0.0901 | |
| Locoregional recurrence | 44 | (6.2) | 27 | (3.8) | 0.0110 | |
| Distant metastasis | 82 | (11.6) | 61 | (8.6) | 0.0521 | |
IQR, interquartile range; PB-RA, paravertebral block-regional anesthesia; GA, general anesthesia; INHA, inhalational; SD, standard deviation; AJCC, American Joint Committee on Cancer; HER2, Human Epidermal Growth Factor Receptor-2; RT, radiotherapy; ASA, American Society of Anesthesiology; CCI, Charlson comorbidity index; T, tumor; N, nodal; pT, pathological tumor stage; pN, pathological nodal stage; ALND, axillary lymph node dissection; SNLB, sentinel lymph node biopsy.